For example, the phase I/II trial NCT0470847 is currently assessing entinostat with bintrafusp alpha, a bifunctional fusion protein targeting TGF-β and PD-L1 in combination with NSH-IL12, a recombinant human IL-12 heterodimer fused to a H-chain of the NHS76 antibody, a necrosis-targeting human IgG1 that will selectively deliver IL-12 to tumor. The gene discussed is CD274; the disease is neoplasm.